Related Experiment Video

Updated: Mar 14, 2026

Visualizing Angiogenesis by Multiphoton Microscopy In Vivo in Genetically Modified 3D-PLGA/nHAp Scaffold for Calvarial Critical Bone Defect Repair
09:34

Visualizing Angiogenesis by Multiphoton Microscopy In Vivo in Genetically Modified 3D-PLGA/nHAp Scaffold for Calvarial Critical Bone Defect Repair

Published on: September 7, 2017

9.9K

Platelet-Derived Growth Factor in Heart Failure

John Medamana1, Richard A Clark2, Javed Butler3

  • 1School of Medicine, Stony Brook University, Stony Brook, NY, 11794-8165, USA.

Handbook of Experimental Pharmacology
|October 9, 2016
PubMed

Insights

Platelet-derived growth factor (PDGF) shows promise for treating heart failure by improving vascular and cardiomyocyte function. Further research is needed to translate these findings into effective clinical therapies for heart conditions.

Area of Science:

  • Cardiovascular Biology
  • Regenerative Medicine
  • Molecular Cardiology

Background:

  • Heart failure, characterized by impaired vascular and cardiomyocyte function, affects both reduced and preserved ejection fraction types.
  • Platelet-derived growth factor (PDGF) family members are crucial for angiogenesis and mesenchymal cell development, suggesting therapeutic potential.

Purpose of the Study:

  • To review the biological role of PDGF in cardiovascular health.
  • To summarize existing research on PDGF's cardiovascular effects, including its administration and impact on stem cell therapy for heart failure.

Main Methods:

  • Literature review of studies on PDGF signaling pathways.
  • Analysis of research investigating PDGF administration in cardiovascular models.
  • Examination of PDGF's role in stem cell-based regenerative therapies.

Main Results:

  • PDGF plays a significant role in vascular and cardiomyocyte function.
  • Animal studies indicate beneficial cardiovascular effects of growth factor therapy, including PDGF.
  • Translating laboratory findings of PDGF therapy into clinical practice remains a challenge.

Conclusions:

  • PDGF holds potential as a therapeutic agent for heart failure.
  • Understanding PDGF signaling and its effects on stem cells is key for future treatments.
  • Bridging the gap between preclinical data and clinical application of PDGF therapy is essential.

Keywords:
AngiogenesisAnimal models of human diseaseBasic science researchGrowth factors/cytokinesHeart failureJournal subject codeMyocardial infarctionStem cells

More Related Videos

Decellularization and Recellularization Methodology for Human Saphenous Veins11:35

Decellularization and Recellularization Methodology for Human Saphenous Veins

Published on: July 27, 2018

14.8K
Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

7.8K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
4.2K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.3K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
497